Disruption of estrogen signaling by developmental exposure to BPA and TBT causes long term functional deficits in zebrafish retina

Read full text
Authors: J. S. Jensen, Logan Ouellette, R. Harris, Peyman Owrang, VICTORIA P. CONNAUGHTON
Cited by: 0
References: 222

Abstract

Bisphenol A (BPA) and tributyltin (TBT) are two endocrine disrupting compounds (EDC) that have opposite effects on estrogen signaling. BPA is an estrogen agonist that binds to all estrogen receptor types. TBT is an aromatase inhibitor that binds to the enzyme aromatase, preventing the synthesis of estrogen from testosterone. Both estrogen receptors and aromatase are localized to the retina and estrogen signaling is required for proper eye and retinal neurogenesis. Abnormal eye growth and retinal changes are reported immediately after developmental exposure to either EDC consistent with the role of estrogen in proper neurogenesis. In this review, we examine the impact of BPA and TBT exposure on the development and function of the visual system. We focus primarily on zebrafish but include data from other species to show trends across vertebrates. We discuss a case study designed to determine if a transient developmental exposure to BPA or TBT has persistent effects that are evident in adults and if these latent outcomes reflect the opposite impact of these compounds on estrogen signaling. Surprisingly, although some opposing outcomes were observed, most differences in adult retinal function were similar between the two compounds, with varying effects noted by concentration and exposure age. Overall, we conclude that developing zebrafish retina is sensitive to EDCs that target estrogenic pathways. However, these findings cannot be explained by estrogenic modulation alone, suggesting additional mechanisms beyond their current established roles.

Fields of Study & Subjects

Effects and risks of endocrine disrupting chemicals Reproductive biology and impacts on aquatic species Estrogen and related hormone effects

Publication details

Journal / source
Frontiers in Pharmacology
Volume
17
Pages
1750796–1750796
Publication date
17 February 2026
Language
EN